Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$290.10 CAD
Change Today +4.87 / 1.71%
Volume 417.2K
As of 2:16 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Howard Bradley Schiller

Chief Financial Officer, Executive Vice President and Director, Valeant Pharmaceuticals International, Inc.
AgeTotal Calculated CompensationThis person is connected to 143 board members in 4 different organizations across 10 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Howard Bradley Schiller has been the Chief Financial Officer and Executive Vice President of Valeant Pharmaceuticals International, Inc. since December 2011 and serves as its Principal Accounting Officer. Mr. Schiller serves as a Chief Financial Officer and an Executive Vice President at Valeant Pharmaceuticals North America LLC. He served as Executive Vice President and Chief Financial Officer of Coria Laboratories, Ltd. He has been Treasurer of Solta Medical, Inc. ...

Read Full Background

Corporate Headquarters*

2150 St. Elzéar boulevard West
Laval, Quebec H7L 4A8


Phone: 514-744-6792
Fax: 514-744-6272

Board Members Memberships*

Former Chief Financial Officer, Executive Vice President, Treasurer, and Director
Chief Financial Officer, Executive Vice President and Director
Former Treasurer and Director
Treasurer and Director


University of Chicago Law School
University of Pennsylvania - The Wharton School

Other Affiliations*

Annual Compensation*

Total Annual Compensation$953,846

Stock Options*

Restricted Stock Awards$23,730,659
All Other Compensation$28,112
Exercisable Options150,000
Exercisable Options Value$14,535,000
Unexercisable Options50,000
Unexercisable Options Value$4,845,000
Total Value of Options$19,380,000
Total Number of Options200,000

Total Compensation*

Total Annual Cash Compensation$3,381,958
Total Short Term Compensation$953,846
Other Long Term Compensation$23,758,771
Total Calculated Compensation$27,112,617
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:CN C$290.10 CAD +4.87


Brenton L. Saunders J.D.Chief Executive Officer, President and Director
Actavis plc
Dilip Shantilal Shanghvi Managing Director, Executive Director and Member of Shareholders/Investors Grievance Committee
Sun Pharmaceutical Industries Limited
Heather Bresch Chief Executive Officer, Executive Director and Member of Science & Technology Committee
Mylan N.V.
Joseph C. Papa Chairman, Chief Executive Officer and President
Perrigo Company Public Limited Company
Yoshihiko Hatanaka Chief Executive Officer, President and Representative Director
Astellas Pharma, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at